Glucosylated pH-sensitive liposomes as potential drug delivery systems

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery

Background:

• Liposomes can be engineered for controlled drug release using pH-sensitive components, crucial for targeting pathological tissues with acidic environments.
• Surface modification of liposomes with sugar moieties (glucosylation) can impart specificity towards lectins, which are often overexpressed in tumor tissues.
• Combining pH-sensitivity and lectin-targeting on liposomes offers a promising strategy for enhanced, site-specific drug delivery.

Purpose of the Study:

• To synthesize and characterize a novel multifunctional pH-sensitive glucosylated amphiphile.
• To evaluate the properties of this amphiphile, both alone and in mixtures with phospholipids, for liposome formulation.
• To compare its performance with a previously developed cationic analogue, focusing on pH-sensitivity, drug release, and lectin interaction.

Main Methods:

• Synthesis and chemical characterization of a novel pH-sensitive glucosylated amphiphile.
• Formulation of liposomes using the synthesized amphiphile, alone and with a natural phospholipid.
• Assessment of liposome properties including pH-sensitivity, lipid organization, drug release kinetics, and interaction with Concanavalin A (Con A).

Main Results:

• The novel glucosylated amphiphile was successfully synthesized and formed stable aggregates and liposomes.
• Liposomes incorporating the pH-sensitive glucosylated amphiphile exhibited pH-dependent drug release profiles.
• The pH-sensitivity significantly influenced the exposure of glucose residues and the liposomes' binding affinity to Concanavalin A.

Conclusions:

• The developed pH-sensitive glucosylated amphiphile is a viable component for creating multifunctional liposomes.
• pH-sensitivity critically modulates drug release, lipid organization, and surface-exposed glucose moieties for targeted delivery.
• These findings support the potential of such advanced liposomes for targeted drug delivery in cancer therapy.